A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
Summary
Third Opinion Trial Synopsis:
This study wants to find out if the quality of certain cells called T cells affects how well a medicine called ide-cel can prevent cancer from coming back in people with a type of cancer called relapsed or refractory multiple myeloma. The people in the study have already had a transplant of certain cells in their blood.
This study wants to find out if the quality of certain cells called T cells affects how well a medicine called ide-cel can prevent cancer from coming back in people with a type of cancer called relapsed or refractory multiple myeloma. The people in the study have already had a transplant of certain cells in their blood.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: